thanks, page-15

Cauggie, I think you are right....when it went to new highs on the RA Capital deal, we all also were led to believe that first dosing was imminent based on what the company told us. (potentially triggering a run to $3 or more in days) In that respect they have greatly failed mum's and pops.....what's new in the world of finance. I posted a couple weeks back that it is time to put up or shut up with the media tour and no clinical patients. Much capital has been squandered over the last few weeks by not leveraging the RA deal with clinical dosing. Mgmt. gave every reason to believe dosing would be started by Feb or Mid March at the very latest (website shows the arrow in clinical for in house HCV program, blatantly false).

I understand we need a perfect first patient, but what if one never makes the cut? I would really like to know how much of the selection is in Duke's hands and the role Beni is playing in screening for first patient during this still PRE CLINICAL phase. Wouldn't we all. (I want a paid Beni staffer on site etc.)

Finally, PF buying those 10,000 shares at $2.00 was brilliant move to support price through capital raising.

All said, the time horizons have now changed both investment wise and science wise. I have not, nor will, sell a single share until things are proven one way or another scientifically. I AM JUST VERY DISAPPOINTED IN THE GUIDANCE MGMT PROVIDED THE MUMS AND POPS WHO HAVE BEEN THE BACKBONE OF THE FINANCING FOR YEARS. Any week now has become months, simply unacceptable.